Ipca Laboratories
Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipca Laboratories's score of 26 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipca Laboratories's reported carbon emissions
In 2023, Ipca Laboratories reported carbon emissions of approximately 124,880,000 kg CO2e for Scope 1 and about 179,114,000 kg CO2e for Scope 2. This reflects a consistent emission pattern from the previous year, with similar figures reported in 2022. However, in 2024, there was a notable increase in Scope 1 emissions to approximately 174,538,000 kg CO2e, while Scope 2 emissions decreased to about 137,345,000 kg CO2e. Ipca Laboratories has committed to a significant reduction target, aiming for a 20% decrease in carbon emissions across both Scope 1 and Scope 2 by 2030. This commitment underscores the company's dedication to enhancing its sustainability practices and reducing its carbon footprint in alignment with industry standards. The reduction targets are set to begin from 2023, indicating a proactive approach to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 124,880,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 179,114,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipca Laboratories is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
